Savara. has been granted a patent for methods to treat acute or chronic heart failure using inorganic nitrite, such as sodium nitrite. The treatment involves inhaling a therapeutically effective dose, which can be administered in a titrated manner without significantly affecting systemic blood pressure or heart rate. GlobalData’s report on Savara gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Savara, Nebulizers and atomisers was a key innovation area identified from patents. Savara's grant share as of June 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.
Treating heart failure using inhaled inorganic nitrite
The granted patent US11986493B2 outlines a method for reducing pulmonary capillary wedge pressure, right atrial pressure, and pulmonary arterial pressure in subjects through the inhalation of inorganic nitrite. The method emphasizes administering a therapeutically effective dose in an escalated titrated manner, ensuring that the treatment does not lead to significant drops in systemic blood pressure or increases in heart rate. The claims specify that this method is applicable to various conditions, including pulmonary hypertension associated with heart failure, interstitial lung disease, and sleep-disordered breathing-related pulmonary hypertension, among others.
The patent further details the formulations of nitrite that can be used, including liquid and dry powder forms, with sodium nitrite being a specific example. The administration protocol involves starting with a lower dose and gradually increasing it to a final dose ranging from 75 mg to 90 mg, achieving plasma concentrations of nitrite between 4 micromolar and 15 micromolar. Additionally, the method aims to improve cardiac index and exercise capacity in subjects, particularly those who are non-responsive to inhaled nitric oxide. Specific patient populations mentioned include those with pulmonary arterial hypertension, potentially linked to connective tissue diseases like scleroderma, as well as individuals with heart failure, whether preserved or reduced ejection fraction.
To know more about GlobalData’s detailed insights on Savara, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
